Mirati Therapeutics, Inc. (MRTX) Valuation According To Analysts

The stock increased 1.77% or $0.25 on October 13, reaching $14.4. The company's stock had a trading volume of 408,583 shares. It has underperformed by 93.21% the S&P500. Short shares fell from 1,141,225 to 1,068,151 over that period. ETE's SI was 55.12 million shares in October as released by FINRA. Logan Cap accumulated 0.16% or 45,542 shares. They now have a United States dollars 18 price target on the stock. It has outperformed by 10.49% the S&P500.

06/06/2016 - Mirati Therapeutics, Inc. had its "overweight" rating reiterated by analysts at Barclays. Therefore 70% are positive. Analysts expect that Mirati Therapeutics will post ($3.31) earnings per share for the current year. The firm earned "Hold" rating on Monday, July 17 by Jefferies. Finally, Cann began coverage on shares of Mirati Therapeutics in a report on Tuesday, September 19th. The stock presently has a consensus rating of Hold and an average target price of $13.88. The firm earned "Neutral" rating on Thursday, September 17 by Piper Jaffray. Mirati Therapeutics has a 52-week low of $2.70 and a 52-week high of $15.50. Leerink Swann maintained it with "Market Perform" rating and $9 target in Friday, September 15 report. The company was maintained on Friday, August 4 by Jefferies.

As of quarter end Ubs Group Ag had bought 1,851 shares growing its holdings by 224.6%. The legal version of this article can be accessed at https://stocknewstimes.com/2017/10/15/mirati-therapeutics-mrtx-buy-rating-reiterated-at-hc-wainwright.html.

Investors sentiment decreased to 0.84 in 2017 Q2. Its down 1.26, from 1.94 in 2017Q1.

Short traders are feeling a little more bearish on shares of Mirati Therapeutics, Inc. of late looking at the rise in short interest. Dimensional Fund Advisors LP purchased a new position in Mirati Therapeutics in the first quarter worth about $677,000. Jefferies Group LLC set a $5.00 price objective on shares of Mirati Therapeutics and gave the stock a hold rating in a research note on Friday, August 4th. Federated Invsts Inc Pa owns 0% invested in Mirati Therapeutics, Inc. (NASDAQ:MRTX) recently. SVP, Chief Science Officer Jamie Christensen disclosed the sale of 770 shares. Finance Architects reported 6,050 shares. Venbio Select Advisor Ltd invested in 1.05% or 2.28 million shares. (NASDAQ:MRTX) for 98,251 shares. Moreover, Alyeska Invest Grp Ltd Partnership has 0.01% invested in Mirati Therapeutics, Inc. The stock of Mirati Therapeutics, Inc.

Company shares are trading at $10.50 which is significantly above $5.54, the 50 day moving average and a great deal higher than the 200 day moving average of $4.54. Meeder Asset Mngmt owns 0% invested in Mirati Therapeutics, Inc. Mirati Therapeutics Inc now has $353.32 million valuation. (NASDAQ:MRTX) to report $-0.85 EPS on November, 2.They anticipate $0.12 EPS change or 12.37% from last quarter's $-0.97 EPS. Citigroup, a New York-based fund reported 1 shares. Zacks Investment Research upgraded shares of Mirati Therapeutics from a "hold" rating to a "buy" rating and set a $4.75 price objective for the company in a research note on Wednesday, May 3rd. (NASDAQ:MRTX). Lmr Llp accumulated 64,760 shares. The stock increased 0.14% or $0.06 during the last trading session, reaching $42.65. Its down 0.03, from 0.87 in 2017Q1. Institutional investors and hedge funds own 60.17% of the company's stock. 72 funds opened positions while 128 raised stakes. Paloma Prns Management has invested 0% in Mirati Therapeutics, Inc. The stock's market capitalization is 359.55M. Broadfin Cap Limited Liability Com holds 2.49M shares or 1.1% of its portfolio. California Employees Retirement Systems invested 0.05% in Energy Transfer Equity LP (NYSE:ETE). 26,464 were reported by Aqr Cap Management Ltd Liability. Broadview Advisors Llc owns 256,663 shares or 1.33% of their U.S. portfolio. Community Bankshares Na reported 700 shares. With an institutional ownership near 61.3%, it carries an earnings per share ratio of -0.61. The Lombard Odier Asset Management Switzerland Sa holds 27,984 shares with $1.34 million value, up from 19,106 last quarter. Benjamin F Edwards And reported 0.01% stake.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Related:

Comments

Latest news

Pretium Resources Inc (PVG) Analysts See $0.11 EPS
RBC Capital Markets maintained the shares of PVG in report on Tuesday, June 28 with "Sector Perform" rating. Technical Communications Corporation (TCCO) has declined 4.00% since October 14, 2016 and is downtrending.

Palo Alto Networks, Inc. (PANW) Director Sells $302020.00 in Stock
On September 1 the company was rated "Overweight" in a report from JP Morgan which is up from the previous "Overweight" rating. Hartline Investment Corp purchased a new stake in Palo Alto Networks during the third quarter valued at about $2,307,000.

Zuma, Okorocha set to provide free education to indigent kids in Africa
I boost of not the sustainability of this project because God is doing this whole thing. Lanre Suraj, CSNAC's Chairman, said in a statement on Sunday the honour bestowed on Mr.

Darden Restaurants, Inc. (DRI) Price Target Lowered to $90.00 at Citigroup Inc
It turned negative, as 46 investors sold DRI shares while 190 reduced holdings. 20 funds opened positions while 24 raised stakes. Darden Restaurants now has a consensus rating of "Hold" and an average target price of $87.82. (NYSE:DRI) for 7,500 shares.

Carbo Ceramics Inc (NYSE:CRR) Institutional Investor Positioning Change
The Firm operates through two divisions: Oilfield Technologies and Services, and Environmental Products and Services. Therefore 22% are positive. 02/06/2017 - Carbo Ceramics , Inc. was upgraded to "buy" by analysts at Evercore ISI.

Other news